Nucleic acid ligands to integrins
AssigneeGilead Sciences, Inc.
InventorsJudy Ruckman, Larry Gold, Andrew Stephens, Nebojsa Janjic
Life of this patent
Estimating the term…
Abstract
Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.
Claims2
A method for detecting a site of deep vein thrombosis in an individual, the method comprising:
- (a) providing a nucleic acid ligand to a αvβ3 or αIIbβ3 mtegrm dimer, wherein said ligand binds to a nucleic acid binding site in said integrin β3 and said nucleic acid ligand conjugated to a radioactive label and wherein said nucleic acid ligand is selected from Table 1, 2 or 3;
- (b) administering said nucleic acid ligand to said individual;
- (c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.
A clot-detection composition comprising a nucleic acid ligand to a αvβ3 or αIIbβ3 integrin and a pharmaceutically-acceptable excipient, wherein said ligand binds to a nucleic acid binding site in said integrin β3 and wherein said nucleic acid ligand is selected from Table 1, 2 or 3.
Dependencies are inferred from the claim text.